BIOCARTIS news, videos and press releases
For more news please use our advanced search feature.
BIOCARTIS - More news...
BIOCARTIS - More news...
- Press release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting
- Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)
- Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)
- Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
- Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting
- Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors
- Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio
- Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit
- Press Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders
- Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023
- Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery
- Press release Biocartis Group NV: Disclosure of transparency notification
- Press release Biocartis Group NV: Disclosure of transparency notification
- Press release Biocartis Group NV: Results of the Annual Shareholders’ Meeting held on 12 May 2023
- Press release Biocartis Group NV: Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test
- Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
- Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO
- Press release Biocartis Group NV: Disclosure of transparency notification
- Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test
- Press release Biocartis Group NV: Biocartis announces 2022 results and 2023 outlook
- Press release Biocartis Group NV: Biocartis announces change in Board composition
- Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
- Press release Biocartis Group NV: Disclosure of transparency notifications
- Press release Biocartis Group NV: Disclosure of a transparency notification
- Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
- Press release Biocartis Group NV: Mandatory Conversion Bondholder Notification
- Press release Biocartis Group NV: Disclosure of a transparency notification
- Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
- Press release Biocartis Group NV: Biocartis Announces 55.91% of Offered Shares Subscribed at Closing of Rights Subscription Period for Holders of Preferential Rights, and Start of Sale of Scrips through Private Placement to Inst. Investors
- Press release Biocartis Group NV: Biocartis launches a rights offering (with extra-legal preferential rights for existing shareholders) of a maximum of 33,476,932 offered shares, amounting to a maximum of EUR 25,107,699.00
